The US Food and Drug Administration’s extensions concerning a Perrigo Company PLC subsidiary’s OTC daily oral contraceptive application didn’t stop with needing additional time to review additional information it requested.
The agency has stretched an advisory panel meeting it will conduct to discuss the application from one day to a day and a half.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?